J Hematol Oncol: PD-1 monoclonal antibody---the efficacy and safety of geptanolimab injection (geptanolimab) in peripheral T-cell lymphoma (PTCL)

T-cell lymphoma (PTCL) is also a cancer, but it is a tumor of the blood system
.
Malignant tumors are formed due to abnormal T cell proliferation and mutation .

Genor Biopharma is a quasi-commercial biopharmaceutical company focusing on the development and commercialization of innovative therapies for oncology and autoimmunity
.
Recently, the company announced that its new PD-1 monoclonal antibody drug candidates geptanolimab (GB226) of the New Drug Application (NDA) has won the State Drug Administration Bureau (NMPA) receiving the drug for the treatment of peripheral T-cell lymphoma (PTCL )

It is worth mentioning that Jiahe Biologics is the first domestic biopharmaceutical company to use PD-1 monoclonal antibody to treat PTCL
.
Patients with relapsed or refractory PTCL have a poor prognosis, and there are great unmet clinical needs worldwide

This is a multi-center, open-label, single-arm phase II clinical trial that evaluates the efficacy and safety of geptanolimab injection (geptanolimab) for the treatment of relapsed or refractory PTCL
.
The study recruited 102 patients from 32 research centers across China

The study showed that geptanolimab injection (geptanolimab) has a significant effect in the treatment of patients with relapsed or refractory PTCL: the ORR assessed by IRC is 36.
3%, and the main subtypes of PTCL can benefit, including ALK-negative anaplastic cells The ORR of lymphoma can reach 58.
3%; in addition, 33.
3% of subjects who have previously failed treatment with chidamide still have remission
.
In the study, the safety characteristics of geptanolimab in the treatment of PTCL patients are similar to similar products, mainly manifested as immune-related adverse events (irAE), which can be treated by symptomatic treatment, drug suspension or withdrawal, and corticosteroids Effective hormone management

It can be seen that the new drug geptanolimab injection (geptanolimab) has a significant effect on the treatment of relapsed or refractory PTCL, which not only prolongs the survival period of patients, but also relieves the patients

In addition, Genozumab injection is currently undergoing clinical trials for the treatment of PD-L1-positive recurrent or metastatic cervical cancer that has failed platinum-containing chemotherapy

Original source:

Shi Y, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, Cen H, Peng Z, Li Y, Fan L, Guo Y, Ma L, Cui J, Gao Y, Yang H, Zhang H, Wang L , Zhang W, Zhang H, Xie L, Jiang M, Zhou H, Shuang Y, Su H, Ke X, Jin C, Du X, Du X, Liu L, Xi Y, Ge Z, Feng R, Zhang Y, Zhou S, Xie F, Wang Q.